Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
SABCS 2017
Quality of Life and Patient-Reported Outcomes in US Patients Enrolled in the MONALEESA-2 Study
SABCS 2017
In the MONALEESA-2 study, the CDK4/6 inhibitor ribociclib, in combination with letrozole, led to significant prolongation of progression-free survival while maintaining quality of life in postmenopausal women with advanced breast cancer.
Read More ›
Efficacy and Safety of Abemaciclib in Patients with Liver Metastases in the MONARCH 1, 2, and 3 Studies
SABCS 2017
The combination of abemaciclib plus endocrine therapy is an effective treatment option in patients with hormone receptor–positive, HER2-negative advanced breast cancer with liver metastases, with significantly higher clinical benefits than those derived from single-agent endocrine therapy.
Read More ›
Videos
Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer
SABCS 2017
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.
Read More ›
Videos
What Differentiates Abemaciclib, Ribociclib, and Palbociclib?
SABCS 2017
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.
Read More ›
Videos
Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor
SABCS 2017
Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor.
Read More ›
Videos
HER2+ Breast Cancer and CDK4/6 Inhibitors
SABCS 2017
Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2+ breast cancer.
Read More ›
Videos
Hot Topics at SABCS 2017
SABCS 2017
Dr Hope Rugo provides an overview of some hot topics being covered at SABCS 2017 in the areas of hormone therapy, immunotherapy, neoadjuvant therapy, and more.
Read More ›
Videos
Abemaciclib, Ribociclib, or Palbociclib for HR+ Metastatic Breast Cancer?
SABCS 2017
Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA-approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.
Read More ›
ER-Positive Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
SABCS 2017
Researchers have identified a CDK4/6 inhibitor–sensitive E2F4 gene expression signature in estrogen receptor (ER)-positive breast cancers resistant to aromatase inhibitors that can potentially identify patients with ER-positive breast cancer who are candidates for adjuvant therapy with CDK4/6 inhibitors in combination with antiestrogens.
Read More ›
Advantageous Polypharmacology of Abemaciclib Revealed by Omics Profiling of CDK4/6 Inhibitors
SABCS 2017
Abemaciclib, but not ribociclib or palbociclib, exhibits inhibition of CDK4/6 plus kinases other than CDK4/6, and induces cell death rather than cytostasis, which may be therapeutically advantageous in patients with hormone receptor‒positive breast cancer that is generally resistant to CDK4/6 inhibitors.
Read More ›
Page 2 of 4
1
2
3
4
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us